Researchers developed a novel gene signature that has prognostic value in patients with multiple myeloma who are treated with immunomodulatory derivatives. READ MORE

Author Insights

Recent research has uncovered a non-inferior, cost-effective alternative to standard therapy for autologous stem cell mobilization in multiple myeloma. The study’s author discusses his findings.

READ MORE

Conferences

Clinicians are now trying to treat multiple myeloma similar to leukemia.

READ MORE

Carol Ann Huff, MD, discusses how to best use newly-approved therapies for multiple myeloma.

READ MORE

Comparing autologous stem cell transplant with bortezomib, melphalan, and prednisone. 

READ MORE

J Code Updates

News

Researchers developed a novel gene signature that has prognostic value in patients with multiple myeloma who are treated with immunomodulatory derivatives.

READ MORE

Patients with relapsed or refractory multiple myeloma should be given individualized treatment based on numerous factors, including biology of the disease and type of relapse.

READ MORE

Results of eight recent clinical trials show that older patients treated for relapsed or refractory multiple myeloma with novel therapies had similar rates of progression-free survival as younger patients.

READ MORE

Daratumumab-based combination therapies are ineffective in patients with multiple myeloma who have been heavily pre-treated or are refractory to one or more agents in a DCT.

READ MORE

Research in Review

A recent cost-effectiveness analysis compared novel agents and chemotherapy for older Medicare patients with multiple myeloma.

READ MORE

According to recent research presented at ASCO, adding which targeting agent to standard of care carfilzomib, lenalidomide, and dexamethasone is a safe and efficacious alternative to ASCT for patients with multiple myeloma?

READ MORE

Targeted therapy against a particular protein has the potential to improve outcomes and fracture-free survival for patients with multiple myeloma.

READ MORE

Adult patients with multiple myeloma who receive a high-dose chemotherapy regimen plus autologous stem-cell transplantation improve their median progression-free survival by 14 months compared with patients who receive chemotherapy alone.

READ MORE